Safety Profile
Retatrutide Side Effects: Frequency & Severity
Retatrutide Phase II data shows GI side effects similar to tirzepatide, slightly more intense due to triple receptor activity.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Serious side effects
1MTC risk (rodent)
Standard incretin-class rodent signal; human relevance uncertain.
Common side effects
5Nausea
35-50%Most prominent in titration phase.
Diarrhea
20-33%Dose-related.
Vomiting
15-30%More common at higher doses.
Decreased appetite
Expected pharmacological effect.
Increased heart rate
Average 5-10 bpm increase — related to glucagon receptor activation.
Uncommon side effects
2Injection site reactions
Mild redness or itching.
Gallbladder disease
Associated with rapid weight loss.
Rare side effects
1Pancreatitis
Standard incretin class concern.
Contraindications
- Personal or family history of MTC
- MEN 2 syndrome
- Known hypersensitivity
Drug interactions
- Insulin and sulfonylureas — increased hypoglycemia risk
- Oral medications with narrow therapeutic index
Special populations
Phase III ongoing; not FDA approved. Pregnancy data limited; not recommended.
Overall safety summary
Retatrutide is under active investigation; current Phase II data shows GI side effects consistent with incretin class. The unique heart rate increase warrants monitoring, especially in patients with pre-existing CV disease.
Retatrutide side effects: FAQ
Why does retatrutide raise heart rate?
Glucagon receptor activation (the third receptor targeted by retatrutide) increases heart rate. This effect is modest (5-10 bpm) but should be considered in patients with existing tachyarrhythmias.